Jennifer L. Crombie - Concepedia

Author

Jennifer L. Crombie

Also Known As

J Crombie, J. Crombie, J. L. Crombie, Jennifer Crombie, Jennifer L Crombie, Jennifer L. Crombie, Jennifer Leigh Crombie, Landsburg, Daniel

167

Publications

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Massachusetts General Hospital Beth Israel Deaconess Medical Center Harvard University The University of Texas MD Anderson Cancer Center

About

Jennifer L. Crombie is an author at Dana-Farber Cancer Institute specializing in oncology, medicine, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	275
2	Immunology	4	4	240
3	Health Sciences	2	2	123
4	Cellular Therapies	1	1	17
5	Marrow Transplantation	1	1	17

Jennifer L. Crombie

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma Matthew J. Frigault, Jörg Dietrich, María Martínez-Lage, Blood	2019	229
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation Philippe Armand, Yi‐Bin Chen, Robert Redd, Blood	2019	178
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy Jennifer L. Crombie, Tara Graff, Lorenzo Falchi, Blood	2024	106
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineHematology	2021	100
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial Matthew S. Davids, Danielle M. Brander, Haesook T. Kim, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineYounger Patients	2019	70
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation Matthew J. Frigault, Philippe Armand, Robert Redd, Blood Advances	2020	65
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas Raphael Koch, Amanda L. Christie, Jennifer L. Crombie, Blood	2018	59
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma Reid W. Merryman, Natasha Edwin, Robert Redd, Blood Advances ImmunologyPathologyImmunotherapyHematological MalignancyOncology	2020	53
Lipopolysaccharide Upregulates α7 Acetylcholine Receptors Mohammed Abdul Sattar Khan, Mina Farkhondeh, Jennifer L. Crombie, Shock	2012	47
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study David Qualls, Nicholas Lambert, Paolo F. Caimi, Blood	2023	40

Page 1